why choose us

First received: December 22, 2025

Clinical Trial: A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Obesity & Overweight

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Single-Dose, Open-Label, Parallel-Group Pharmacokinetic Study of VCT220 in Subjects With Moderate Renal Impairment and Matched Subjects With Normal Renal Function

Brief Summary: This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of VCT220 (other name: CX11) in subjects with moderate renal impairment compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal function.The results of this study will provide scientific evidence to support appropriate clinical dosing recommendations of VCT220 in subjects with renal impairment.

Read more